Cleared Traditional

K924637 - HEMOCHRON CITRA ONESTEP APTT/FAC VI SINGSHOT APTT

K924637 is an FDA 510(k) clearance for HEMOCHRON CITRA ONESTEP APTT/FAC VI SIN..., manufactured by International Technidyne Corp.. The device is a Class 2 Hematology device with product code GFO cleared through the Traditional 510(k) pathway after a 148-day FDA review.

K924637 · International Technidyne Corp. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1993
Decision
148d
Days
Class 2
Risk

K924637 is an FDA 510(k) clearance for the HEMOCHRON CITRA ONESTEP APTT/FAC VI SINGSHOT APTT. Classified as Activated Partial Thromboplastin (product code GFO), Class II - Special Controls.

Submitted by International Technidyne Corp. (Edison, US). The FDA issued a Cleared decision on January 27, 1993 after a review of 148 days - within the typical 510(k) review window.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7925 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all International Technidyne Corp. devices

FDA 510(k) Submission Details - K924637

510(k) Number K924637 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 01, 1992
Decision Date January 27, 1993
Days to Decision 148 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
35d slower than avg
Panel avg: 113d · This submission: 148d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GFO Device Classification - Class 2, Special Controls

Product Code GFO Activated Partial Thromboplastin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7925
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GFO Activated Partial Thromboplastin

All 43
Devices cleared under the same product code (GFO) and FDA review panel - the closest regulatory comparables to K924637.
APTT-ES REAGENT
K934351 · Medical Diagnostic Technologies, Inc. · Dec 1993
PATHROMTIN
K932011 · Behring Diagnostics, Inc. · Oct 1993
ACS APCT REAGENT, MODIFIED
K926012 · Analytical Control Systems, Inc. · Apr 1993
HEMOCHRON DIRECT DRAW APTT/FAC VI VACU-APTT
K924638 · International Technidyne Corp. · Jan 1993
STACLOT LA TEST KIT
K923731 · American Bioproducts Co. · Dec 1992
PLATELIN L
K921396 · Organon Teknika Corp. · Oct 1992